tetano
Editor, Senior Moderator
Sci Immunol
. 2024 Aug 9;9(98):eadp9279.
doi: 10.1126/sciimmunol.adp9279. Epub 2024 Aug 9. SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines
Ida Paciello[SUP] 1 [/SUP], Giuseppe Maccari[SUP] 2 [/SUP], Giulio Pierleoni[SUP] 1 3 [/SUP], Federica Perrone[SUP] 1 3 [/SUP], Giulia Realini[SUP] 1 [/SUP], Marco Troisi[SUP] 1 [/SUP], Gabriele Anichini[SUP] 4 [/SUP], Maria Grazia Cusi[SUP] 4 [/SUP], Rino Rappuoli[SUP] 3 5 [/SUP], Emanuele Andreano[SUP] 1 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.
. 2024 Aug 9;9(98):eadp9279.
doi: 10.1126/sciimmunol.adp9279. Epub 2024 Aug 9. SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines
Ida Paciello[SUP] 1 [/SUP], Giuseppe Maccari[SUP] 2 [/SUP], Giulio Pierleoni[SUP] 1 3 [/SUP], Federica Perrone[SUP] 1 3 [/SUP], Giulia Realini[SUP] 1 [/SUP], Marco Troisi[SUP] 1 [/SUP], Gabriele Anichini[SUP] 4 [/SUP], Maria Grazia Cusi[SUP] 4 [/SUP], Rino Rappuoli[SUP] 3 5 [/SUP], Emanuele Andreano[SUP] 1 [/SUP]
Affiliations
- PMID: 39121195
- DOI: 10.1126/sciimmunol.adp9279
The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.